BACKGROUND: In high-income countries, viral load is routinely measured to detect failure of antiretroviral therapy (ART) and guide switching to second-line ART. Viral load monitoring is not generally available in resource-limited settings. We examined switching from nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens to protease inhibitor-based regimens in Africa, South America and Asia. DESIGN AND METHODS: Multicohort study of 17 ART programmes. All sites monitored CD4 cell count and had access to second-line ART and 10 sites monitored viral load. We compared times to switching, CD4 cell counts at switching and obtained adjusted hazard ratios for switching (aHRs) with 95% confidence intervals (CIs) from random-e...
As antiretroviral treatment (ART) programmes in resource-limited settings mature, more patients are ...
OBJECTIVES: To determine rates and causes of switching from first- to second-line antiretroviral tre...
Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiret...
International audienceBACKGROUND: In high-income countries, viral load is routinely measured to dete...
BACKGROUND HIV-1 viral load (VL) testing is recommended to monitor antiretroviral therapy (ART) b...
Background HIV-1 viral load testing is recommended to monitor antiretroviral therapy (ART) but is n...
Background: Viral load (VL) is recommended for monitoring the response to highly active antiretrovir...
Objectives: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinica...
Background Viral load (VL) is recommended for monitoring the response to highly active antiretrovira...
In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries rec...
OBJECTIVES: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinica...
In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries rec...
Background. @nbsp; Antiretroviral treatment programs in sub-Saharan Africa have high rates of early ...
BackgroundCurrent World Health Organization (WHO) antiretroviral therapy (ART) guidelines define vir...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
As antiretroviral treatment (ART) programmes in resource-limited settings mature, more patients are ...
OBJECTIVES: To determine rates and causes of switching from first- to second-line antiretroviral tre...
Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiret...
International audienceBACKGROUND: In high-income countries, viral load is routinely measured to dete...
BACKGROUND HIV-1 viral load (VL) testing is recommended to monitor antiretroviral therapy (ART) b...
Background HIV-1 viral load testing is recommended to monitor antiretroviral therapy (ART) but is n...
Background: Viral load (VL) is recommended for monitoring the response to highly active antiretrovir...
Objectives: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinica...
Background Viral load (VL) is recommended for monitoring the response to highly active antiretrovira...
In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries rec...
OBJECTIVES: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinica...
In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries rec...
Background. @nbsp; Antiretroviral treatment programs in sub-Saharan Africa have high rates of early ...
BackgroundCurrent World Health Organization (WHO) antiretroviral therapy (ART) guidelines define vir...
Background. Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortali...
As antiretroviral treatment (ART) programmes in resource-limited settings mature, more patients are ...
OBJECTIVES: To determine rates and causes of switching from first- to second-line antiretroviral tre...
Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiret...